RESUMEN
BACKGROUND: Assessment of the joint cartilage using ultrasound imaging is important. OBJECTIVE: Our aim was to investigate the reliabilities of ultrasonographic measurements for talus dome (TCT) and metacarpal cartilage thicknesses (MCT). METHODS: Twenty healthy volunteers were recruited in the study. Every day, five physiatrists measured eight joint cartilage thicknesses. They repeated all the measurements in five consecutive days. RESULTS: Intra-observer intraclass correlation coefficient (ICC) values were "excellent" for all MCTs, except for the 3rd left MCT on the 1st day, 4th left MCT on the 1st day and 4th right MCT on the 3rd day which were "good". They were "excellent" for the TCT measurements, except for the left side on the 3rd day and the right side on the 4th day which were "good". Inter-observer ICC values pertaining to the 2nd MCT measurements were "excellent" for all sonographers. Third and 4th MCT measurements (at least one side) were "excellent" for four and three sonographers, respectively. On the other hand, while TCT measurements were "excellent" for 4 sonographers. CONCLUSIONS: Our results have shown that sonographic measurements of MCT and TCT have good to excellent reliabilities in healthy adults. These findings support the use of ultrasound for cartilage assessment in various diseases.
Asunto(s)
Articulación del Tobillo/diagnóstico por imagen , Cartílago Articular/diagnóstico por imagen , Articulación Metacarpofalángica/diagnóstico por imagen , Astrágalo/diagnóstico por imagen , Adulto , Femenino , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Reproducibilidad de los Resultados , Ultrasonografía , Adulto JovenRESUMEN
Dendritic cells (DCs) are considered a very promising arm to activate the immune system in immunotherapeutic strategies against cancer. DCs are the most powerful antigen-presenting cells (APCs), being highly efficient at generating robust immune responses. They are also considered the center of the immune system, since they provide a crucial link between both innate and adaptive immune responses. Thus, DC-based cancer immunotherapy aims to take advantage of these unique characteristics of DCs to better fight cancer. During the last decade, they have been the subject of numerous studies intending to develop immunotherapeutic strategies against cancer through vaccination. For this purpose, it is essential to gain a better insight into DC immunobiology, regulation of innate and adaptive immune systems, and tumor microenvironment, as well as applying the latest advances in science in order to boost their enormous anti-tumor immunotherapeutic potential. In this review, we will hold focus on DC immunobiology (from their origin, location, and special properties and distinct subsets to the innate and adaptive immunity), on the new concept of cancer immunoediting, and on the knowledge given by clinical trials using DC vaccines. Finally, future perspectives for this emerging field are highlighted.
Asunto(s)
Vacunas contra el Cáncer/inmunología , Células Dendríticas/inmunología , Inmunoterapia Adoptiva/métodos , Neoplasias/terapia , Inmunidad Adaptativa , Animales , Ensayos Clínicos como Asunto , Células Dendríticas/trasplante , Humanos , Inmunidad Innata , Neoplasias/inmunología , Microambiente TumoralRESUMEN
Dendritic cells (DCs) are versatile elements of the immune system and are best known for their unparalleled ability to initiate and modulate adaptive immune responses. During the past few decades, DCs have been the subject of numerous studies seeking new immunotherapeutic strategies against cancer. Despite the initial enthusiasm, disappointing results from early studies raised some doubts regarding the true clinical value of these approaches. However, our expanding knowledge of DC immunobiology and the definition of the optimal characteristics for antitumor immune responses have allowed a more rational development of DC-based immunotherapies in recent years. Here, after a brief overview of DC immunobiology, we sought to systematize the knowledge provided by 20 years of clinical trials, with a special emphasis on the diversity of approaches used to manipulate DCs and their consequent impact on vaccine effectiveness. We also address how new therapeutic concepts, namely the combination of DC vaccines with other anticancer therapies, are being implemented and are leveraging clinical outcomes. Finally, optimization strategies, new insights, and future perspectives on the field are also highlighted.